Incretin & metabolic

If you’re here, you’ve probably watched someone visibly slim down on a weekly shot, heard “Ozempic” and “Mounjaro” more times than you can count, and wanted the straight version of what these things actually are.

GLP-1 and incretin peptides are lab-made copies of the gut hormones your body releases after a meal, the ones that tell your brain you’re full and your pancreas to handle sugar. People come here for three things: real fat loss, a quieter appetite, and steadier blood sugar. This is the most human-proven corner of the whole peptide reference.

What people actually come here for

People land on the GLP-1 category chasing one of three things, and usually all three at once: fat that finally comes off, an appetite that stops running the show, and blood sugar that behaves. The most-repeated report from users, though, isn’t about the scale. It’s that the constant background chatter about food, the stuff people have taken to calling “food noise,” goes quiet for the first time in years.

The honest version includes the parts the before-and-afters skip. Nausea and other gut side effects are common, especially while the dose is climbing. Weight tends to come back when people stop, because these drugs quiet appetite while you take them rather than resetting it for good. And the results that make headlines are trial averages measured with lifestyle support behind them, not a promise for any one body.

How this class actually works

GLP-1 agonists work by mimicking a gut hormone called GLP-1 (glucagon-like peptide-1), one of the “incretin” signals your intestine fires after you eat. The natural hormone taps your brain on the shoulder to say you’re full and then fades within minutes; these drugs leave their hand on your shoulder for a week. That’s the whole trick: a longer-lasting copy of a satiety signal your body already uses.

The newer molecules pull more than one lever at once. Tirzepatide adds GIP, a second incretin hormone. Retatrutide adds a third, glucagon, which nudges energy burn on top of appetite. And cagrilintide works a different satiety pathway entirely by mimicking amylin, which is why it’s usually studied paired with semaglutide rather than run on its own. More levers, so far, has meant more weight lost.

The honest state of the evidence

Here’s what sets this category apart from almost everything else we cover: the evidence is not thin. This is the one part of the peptide world with large, placebo-controlled human trials and FDA approvals sitting under the headline claims, not mouse data and hope.

The numbers are the reason people pay attention. In the STEP 1 trial, adults with obesity on once-weekly semaglutide lost about 15% of their body weight over 68 weeks, versus roughly 2-3% on placebo (Wilding et al., STEP 1). Tirzepatide went further in SURMOUNT-1: up to 20.9% at the top dose over 72 weeks (SURMOUNT-1). And the triple agonist retatrutide, still investigational, reported 24.2% at its highest dose over 48 weeks in its phase 2 trial (phase 2 RCT). That’s a different league from the diet drugs that came before.

So where’s the hype? Two places. First, the frontier compounds, retatrutide and the cagrilintide-plus-semaglutide combos, are posting the biggest numbers but aren’t approved yet, so their long-term safety record is still being written. Second, and more practically, a lot of what gets sold online as “research” semaglutide or tirzepatide is gray-market powder whose real identity, dose, and purity ride on a vendor’s say-so. A lab report a seller ran on their own product proves they can print a PDF, not that the vial matches it.

The direction of travel is up and to the right. Each generation, from single GLP-1, to the GIP-plus-GLP-1 duals, to the triple agonists and amylin combos reading out now, has pushed weight loss higher. This is one of the few places in the reference where “the proof is arriving” undersells it: it already arrived, and the next wave is landing on a schedule.

Who this category is for

GLP-1 and incretin peptides fit the person dealing with real, stubborn weight or blood-sugar trouble who wants an option with actual human trials behind it. It’s the rare peptide category where the mainstream, FDA-approved route exists, so it’s also the one where reaching for an unregulated gray-market powder trades away the single thing that makes it special: proof.

It’s a worse fit for someone chasing a few vanity pounds who isn’t ready for ongoing cost, weekly injections, gut side effects, and the strong odds of regain after stopping. And nothing here is a decision to make off a category page: the approved versions are prescription drugs, dispensed through a doctor, for good reason.

So, back to that weekly shot you keep hearing about. The short version: this is the most proven corner of the peptide world, the headline results are real and large, and the next generation is only pushing them higher. The move is to start with the compound, not the hype. Semaglutide and tirzepatide are the proven anchors; retatrutide and cagrilintide are the frontier. If cost is your real question, the cost-per-dose calculator does the math, and if you’re staring at a gray-market vial, the reconstitution calculator handles the arithmetic without pretending to hand you a protocol.

Metabolism isn’t the only lever these compounds touch, either. The growth-hormone peptides get chased for body composition, and the longevity and mitochondrial group, where MOTS-c lives, comes at metabolic health from the energy side. All of it sits inside the wider peptide reference.